Exploring combination therapy centered on targeted immunotherapy for advanced hepatocellular carcinoma:a beacon of hope  

作　　者：Yanbin Wang Yuqi Wu Hong Zhang Jing Wang Anping Song Hong Qiu Xianglin Yuan Hua Xiong Yanmei Zou 

机构地区：[1]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China

出　　处：《Oncology and Translational Medicine》2024年第6期292-299,共8页肿瘤学与转化医学（英文版）

摘　　要：Hepatocellular carcinoma(HCC)is an aggressive malignancy that is highly prevalent worldwide.It is often diagnosed at an advanced stage,which poses challenges for curative treatment and leads to an unfavorable prognosis.The introduction of targeted therapy drugs,such as tyrosine kinase inhibitors,and immunotherapeutic drugs,including immune checkpoint inhibitors,has substantially improved the thera-peutic effectiveness for advanced HCC.However,their efficacy remains suboptimal,owing to challenges related to patient responsiveness and drug resistance.To address these challenges,researchers have investigated combination therapies,including targeted immunother-apy,and triple therapies based on targeted immunotherapy,such as a combination of radiotherapy and targeted immunotherapy.In ad-dition,they conducted a comprehensive investigation of potential new targets and drugs,yielding a series of significant findings.This re-view presents an outline of the treatment mechanisms and associated clinical research findings on mainstream targeted therapies,immu-notherapies,and combination therapies.It also summarizes the current status of combination therapies for advanced HCC and anticipates future developments and trends in this field.

关 键 词：Hepatocellular carcinoma Targeted immunotherapy Locoregional therapy Combination therapy 

分 类 号：R735.7[医药卫生—肿瘤]